IXOA regimen, irinotecan (I), capecitabine (X), oxaliplatin (O), and bevacizumab (A), as first-line therapy for advanced unresectable colorectal cancer (aCRC): Preliminary results.
Jean Alfred Maroun
Research Funding - Roche; Sanofi
Derek J. Jonker
Consultant or Advisory Role - Roche (U); Sanofi (U)
Research Funding - Sanofi
M. Christine Cripps
No relevant relationships to disclose
Rakesh Goel
No relevant relationships to disclose
Timothy R. Asmis
No relevant relationships to disclose
Rachel Anne Goodwin
No relevant relationships to disclose
Nirit Yarom
No relevant relationships to disclose
Horia Marginean
No relevant relationships to disclose